Which antibiotics should we report in an antibiogram, and how?;¿qué antibióticos debemos informar en el antibiograma y cómo?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 10, 2010, Pages 737-741

  Alós, Juan Ignacio ^a,b   Rodríguez Baño, Jesús ^c,d  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Antibiogram; Antibiotic stewardship; Antibiotic susceptibility testing; Antimicrobial resistance; Clinical Microbiology

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC SENSITIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; PRACTICE GUIDELINE; REVIEW;

EID: 78649661060     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2010.05.003     Document Type: Article

References (30)

1. J.D. Turnidge, M.J. Ferraro, and J.H. Jorgensen Susceptibility testing methods: general considerations P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, M.A. Pfaller, Manual of Clinical Microbiology 9th ed 2007 ASM Press Washington 1146 1151
2. R.C. Moellering, and G.M. Eliopoulos Principles of anti-infective therapy G.L. Mandell, J.E. Bennett, R. Dolin, Principles and Practice of Infectious Diseases 2005 Elsevier Churchill Livingstone Philadelphia 242 254
3. T.H. Dellit, R.C. Owens, J.E. McGowan, D.N. Gerding, R.A. Weinstein, and J.P. Burke Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship Clin Infect Dis 44 2007 159 177
4. F.M. MacKenzie, M.J. Struelens, K.J. Towner, I.M. Gould on behalf of the ARPAC Steering Group and the ARPAC Consensus Conference Participants Report of the Consensus Conference on Antibiotic Resistance, Prevention and Control (ARPAC) Clin Microbiol Infect 11 2005 937 954
5. D. Nathwani on behalf of Scottish Medicines Consortium (SMC) Short Life Working Group The Scottish Executive Health Department Healthcare Associated Infection Task Force. Antimicrobial prescribing policy and practice in Scotland: recommendations for good antimicrobial practice in acute hospitals J Antimicrob Chemother 57 2006 1189 1196
6. C. MacDougall, and R.E. Polk Antimicrobial stewardship programs in health care systems Clin Microbiol Rev 18 2005 638 656
7. J. Turnidge, and D.L. Paterson Setting and revising antibacterial susceptibility breakpoints Clin Microbiol Rev 20 2007 391 408
8. M.H. Kollef Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front Clin Infect Dis 47 Suppl 1 2008 S3 S13
9. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S20 2010 Clinical and Laboratory Standards Institute Wayne, Pennsylvania
10. EUCAST. Clinical breakpoints. Clinical breakpoints bacteria [consultado 15/4/2010]. Disponible en: http://www.eucast.org/clinical-breakpoints/.
11. Comit de l'antibiogramme de la Socit Franaise de Microbiologie. Recommandations 2010. [consultado 12/1/2010]. Disponible en: http://www.sfm.asso.fr/publi/general.php?pa=1
12. MENSURA Recomendaciones del grupo MENSURA para la seleccin de antimicrobianos para el estudio de sensibilidad y criterios de interpretacin del antibiograma Rev Esp Quimioter 13 2000 73 86
13. C.R. Frei, N.P. Wiederhold, and D.S. Burgess Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokineticpharmacodynamic models with Monte Carlo simulation J Antimicrob Chemother 61 2008 621 628
14. P.G. Ambrose, S.M. Bhavnani, C.M. Rubino, A. Louie, T. Gumbo, and A. Forrest Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore Clin Infect Dis 44 2007 79 86
15. F. Soriano Aspectos farmacocinticas y farmacodinmicos para la lectura interpretada del antibiograma Enferm Infecc Microbiol Clin 2010 En prensa (en el presente nmero)
16. A. Soriano, F. Marco, J.A. Martnez, E. Pisos, M. Almela, and V.P. Dimova Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 2008 193 200
17. M.H. Kollef Limitations of vancomycin in the management of resistant staphylococcal infections Clin Infect Dis 45 2007 S191 S195
18. T.P. Lodise, B. Lomaestro, and G.L. Drusano Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy Clin Infect Dis 44 2007 357 363
19. S.V. Bhat, A.Y. Peleg, T.P. Lodise, K.A. Shutt, B. Capitano, and B.A. Potoski Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms Antimicrob Agents Chemother 51 2007 4390 4395
20. R. Cantn Lectura interpretada del antibiograma: ¿ejercicio intelectual o necesidad clnica? Enferm Infecc Microbiol Clin 20 2002 176 185
21. P. Courvalin Interpretive reading of antimicrobial susceptibility tests ASM News 58 1992 368 375
22. D.M. Livermore, T.G. Winstanley, and K.P. Shannon Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes J Antimicrob Chemother 48 Suppl 1 2001 87 102
23. V. Baos Vicente, A. Barbero Gonzlez, E. Diogne Fadini, A. Eguilleor Villena, T. Eyaralar Riera, and J. Ibez Fernndez Documento de consenso sobre la utilizacin de antibiticos en atencin primaria Aten Primaria 38 2006 174 177
24. M.G. Page Anti-MRSA beta-lactams in development Curr Opin Pharmacol 5 2006 480 485
25. J.W. Chow, M.J. Fine, D.M. Shlaes, J.P. Quinn, D.C. Hooper, and M.P. Johnson Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy Ann Intern Med 115 1991 585 590
26. M.J. Schwaber, C.S. Graham, B.E. Sands, H.S. Gold, and Y. Carmeli Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species Antimicrob Agents Chemother 47 2003 1882 1886
27. M.P. Montanari, E. Tili, I. Cochetti, M. Mingoia, A. Manzin, and P.E. Varaldo Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy Microb Drug Resist 10 2004 209 217
28. E. Perez-Trallero, J.M. Marimon, A. Gonzalez, M. Ercibengoa, and J. Larruskain In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease Clin Infect Dis 41 2005 560 564
29. M. De Cueto, J.M. Rodrguez, M.J. Soriano, L. Lpez-Cerero, J. Venero, and A. Pascual Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation J Clin Microbiol 46 2008 1558 1560
30. R. Cantn, J.I. Als, F. Baquero, J Calvo, J Campos, and J Castillo Recomendaciones para la seleccin de antimicrobianos en el estudio de la sensibilidad in vitro con sistemas automticos y semiautomticos Enferm Infecc Microbiol Clin 25 2007 394 400